REG - Seed Innovations Ltd - Investee Company Update: Little Green Pharma Ltd

Seed InnovationsAnnouncement

22/03/2023 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230322:nRSV8773Ta&default-theme=true

RNS Number : 8773T  Seed Innovations Limited  22 March 2023

22 March 2023

 

SEED Innovations Limited

("SEED" or the "Company")

Investee Company Update: Little Green Pharma Ltd

SEED Innovations Ltd, the AIM-quoted company investing in fast-growing and
industry-leading businesses with a focus on the medical cannabis, health, and
wellness space, notes an announcement released on the ASX by its portfolio
company, Little Green Pharma Ltd ('LGP').

The Company owns 7,324,796 ordinary shares in LGP representing 2.8% of LGP's
issued share capital. The Company does not currently intend to participate in
the fundraise.

The following extract from the announcement is set out without material
changes or adjustments and the announcement in full can be accessed from the
following
link:   https://investor.littlegreenpharma.com/site/investor-centre/asx-announcements
(https://investor.littlegreenpharma.com/site/investor-centre/asx-announcements)

 

Start of Little Green Pharma Ltd announcement:

21 March 2023

REQUEST FOR TRADING HALT

Little Green Pharma Ltd ("Little Green Pharma" or the "Company") requests an
immediate voluntary halt in the trading of the Company's securities (ASX:LGP)
quoted on the Australian Securities Exchange ("ASX") in accordance with ASX
Listing Rule 17.1.

The trading halt is requested pending announcements by the Company to the
market regarding a proposed capital raise ("Stated Purpose").

In accordance with ASX Listing Rule 17.1, the Company provides the following
information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its
continuous disclosure obligations as the Company expects to make an
announcement to the market in relation to the Stated Purpose above.

2. The Company requests that the trading halt remains in place until the
earlier of commencement of normal trading on Friday, 24 March 2023, or when an
announcement regarding the Stated Purpose has been released to the market.

3. The Company expects to make the announcement to the market before the
commencement of normal trading on Friday, 24 March 2023.

4. The Company is not aware of any reason why the trading halt should not be
granted or of any further information necessary to inform the market about the
trading halt.

This request for a trading halt is authorised by the Board of Directors of the
Company.

 

End of Little Green Pharma Ltd announcement

 

- Ends -

For further information on the Company please visit:  www.seedinnovations.co
(http://www.seedinnovations.com/)    or contact:

 

 Ed McDermott       SEED Innovations Ltd         E: info@seedinnovations.co

 Lance de Jersey
 James Biddle       Beaumont Cornish Limited,    T: (0)20 7628 3396

 Roland Cornish     Nomad
 Isabella Pierre    Shard Capital Partners LLP   T: (0)20 7186 9927

 Damon Heath        Broker
 Catherine Leftley  St Brides Partners Ltd,      E: info@stbridespartners.co.uk

 Isabelle Morris    Financial PR

 Max Bennett

 

 

 

Notes

Seed Innovations Ltd

SEED Innovations is an AIM quoted investment company focused primarily on
disruptive high growth life sciences and technology businesses particularly
within the medical cannabis arena. The Company's strategy is to identify
early-stage opportunities that have an upcoming investment catalyst and grow
its portfolio in terms of value whilst limiting the number of investee
companies to a level where relevant time can be devoted to each.

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically
diverse medicinal cannabis business with operations from cultivation and
production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its
own-branded and white-label ranges of GMP-grade medicinal cannabis products,
being a 21,500m2 cultivation and 4,000m2 GMP manufacturing facility capable of
producing over 30 tonnes of medicinal cannabis biomass per annum located in
Denmark (EU) and an indoor cultivation and manufacturing facility located in
Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass
per annum.

Little Green Pharma products comply with all required Danish Medicines Agency
and Therapeutic Goods Administration regulations and testing requirements.
With a growing range of products containing differing ratios of active
ingredients, Little Green Pharma supplies medical-grade cannabis products to
Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global
medicinal cannabis market and is actively engaged in promoting education and
outreach programs, as well as participating in clinical investigations and
research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go
to: www.littlegreenpharma.com (http://www.littlegreenpharma.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDPPUCPWUPWGUP